Gregory J. Divis has been appointed chief executive officer, Avadel Pharmaceuticals plc. Mr. Divis has served in the role on an interim basis since January 2019.  

Mr. Divis joined the company as chief commercial officer in January 2017. He was promoted to chief operating officer in March 2018. Prior to joining Avadel, he served as an executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. From 2010 to 2014, he was president and chief executive officer of Lumara Health, a specialty branded pharmaceutical company focused on women’s health. Previously, Mr. Divis served as vice president, business development and lifecycle management at Sanofi-Aventis.

“Since being named Interim CEO at the beginning of 2019, Greg has done an excellent job leading the Company through rapid restructuring while directing our focus toward the successful development of FT218, our novel once-nightly therapy for narcolepsy patients,” said Geoffrey Glass, Chairman of Avadel’s Board of Directors. “Under Greg’s leadership, we have successfully executed on a series of restructuring initiatives to simplify our business and restore our financial and operational health. While these initiatives required a number of difficult decisions, they have positioned Avadel to maximize the value of the Company and progress our lead clinical candidate, FT218. The entire Board is highly confident in Greg and his ability to continue leading the Company.”